Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19203745 | 0.86 | SSTR4 (0.43) | SSTR4EPHX2GAASLC22A12HSD11B1 | |
| SCHEMBL23419080 | 0.83 | SSTR4 (0.41) | SSTR4EPHX2GAASLC22A12HSD11B1 | |
| SCHEMBL29502462 | 0.81 | SSTR4 (0.47) | SSTR4EPHX2GAASLC22A12NFE2L2 | |
| SCHEMBL11955143 | 0.81 | SSTR4 (0.46) | SSTR4EPHX2GAASLC22A12HSD11B1 | |
| SCHEMBL23419232 | 0.80 | SSTR4 (0.41) | SSTR4EPHX2GAASLC22A12HSD11B1 | |
| SCHEMBL31608519 | 0.78 | EPHX2 (0.44) | SSTR4EPHX2HSD11B1NFE2L2TAAR1 | |
| SCHEMBL8436654 | 0.78 | EPHX2 (0.44) | SSTR4EPHX2HSD11B1NFE2L2TAAR1 | |
| SCHEMBL16252852 | 0.78 | SSTR4 (0.44) | SSTR4EPHX2GAASLC22A12HSD11B1 | |
| SCHEMBL16021178 | 0.78 | SSTR4 (0.44) | SSTR4EPHX2GAASLC22A12HSD11B1 | |
| SCHEMBL20920985 | 0.78 | TDP1 (0.35) | SSTR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027257-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | KANION USA INC. | 2023-01-26 | — | — | US | disclosed |
| US-11242332-B2 | Method for producing benzimidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-02-08 | — | — | US | disclosed |
| US-20200071295-A1 | METHOD FOR PRODUCING BENZIMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2020-03-05 | — | — | US | disclosed |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027257-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | SSTR4 4809/4885EPHX2 2935/4885GAA 1083/4885 |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | SSTR4 4809/4885EPHX2 2935/4885GAA 1083/4885 |
| US-11242332-B2 | Method for producing benzimidazole derivative | CYP3A4, CYP3A5, CYP3A43 | SSTR4 3487/4885EPHX2 2465/4885GAA 584/4885 |
| US-20200071295-A1 | METHOD FOR PRODUCING BENZIMIDAZOLE DERIVATIVE | CYP3A4, CYP3A5, CYP3A43 | SSTR4 3487/4885EPHX2 2465/4885GAA 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.